We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Adma Biologics (ADMA) Outpaced the Stock Market Today
Read MoreHide Full Article
Adma Biologics (ADMA - Free Report) closed at $15.05 in the latest trading session, marking a +2.66% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.34%. Elsewhere, the Dow gained 0.09%, while the tech-heavy Nasdaq added 0.42%.
The infectious disease drug developer's stock has dropped by 14.77% in the past month, falling short of the Medical sector's gain of 1.97% and the S&P 500's gain of 3.54%.
Analysts and investors alike will be keeping a close eye on the performance of Adma Biologics in its upcoming earnings disclosure. The company is predicted to post an EPS of $0.16, indicating a 6.67% growth compared to the equivalent quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $130.1 million, indicating a 8.56% increase compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates project earnings of $0.57 per share and a revenue of $506.7 million, demonstrating changes of +16.33% and +18.82%, respectively, from the preceding year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Adma Biologics. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Currently, Adma Biologics is carrying a Zacks Rank of #3 (Hold).
In terms of valuation, Adma Biologics is currently trading at a Forward P/E ratio of 25.72. This valuation marks a premium compared to its industry average Forward P/E of 18.92.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 80, finds itself in the top 33% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Adma Biologics (ADMA) Outpaced the Stock Market Today
Adma Biologics (ADMA - Free Report) closed at $15.05 in the latest trading session, marking a +2.66% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.34%. Elsewhere, the Dow gained 0.09%, while the tech-heavy Nasdaq added 0.42%.
The infectious disease drug developer's stock has dropped by 14.77% in the past month, falling short of the Medical sector's gain of 1.97% and the S&P 500's gain of 3.54%.
Analysts and investors alike will be keeping a close eye on the performance of Adma Biologics in its upcoming earnings disclosure. The company is predicted to post an EPS of $0.16, indicating a 6.67% growth compared to the equivalent quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $130.1 million, indicating a 8.56% increase compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates project earnings of $0.57 per share and a revenue of $506.7 million, demonstrating changes of +16.33% and +18.82%, respectively, from the preceding year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Adma Biologics. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Currently, Adma Biologics is carrying a Zacks Rank of #3 (Hold).
In terms of valuation, Adma Biologics is currently trading at a Forward P/E ratio of 25.72. This valuation marks a premium compared to its industry average Forward P/E of 18.92.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 80, finds itself in the top 33% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.